Evidence map›Paper›PMID 40728626›Full record

ArticleAnnals of hematology2025

Pola-R-CHP performed well in first-line Polarix trial-ineligible and IPI 0-1 DLBCL patients : Article type: research.

Yuhong Ren, Luya Cheng, Jingli Zhuang, Zhimei Wang, Ling Yuan, Zhixiang Cheng, Yang Ke, Weiguang Wang, Jing Li, Peng Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yuhong RenDepartment of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.ORCID http://orcid.org/0000-0003-0330-4125
Luya ChengDepartment of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.
Jingli ZhuangDepartment of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.
Zhimei WangDepartment of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.
Ling YuanDepartment of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.
Zhixiang ChengDepartment of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.
Yang KeDepartment of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.
Weiguang WangDepartment of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.
Jing LiDepartment of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China.
Peng LiuDepartment of Hematology, Zhongshan Hospital, Fudan University, 180 Fenglin Road, Shanghai, China. liu.peng@zs-hospital.sh.cn.ORCID http://orcid.org/0000-0002-9639-6606

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Polatuzumab vedotin, rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) improved progression-free survival (PFS) of diffuse large B-cell lymphoma (DLBCL) in Polarix study. But little evidence has been provided for patients with lower international prognostic index (IPI) scores or ineligible for clinical trials. We retrospectively enrolled 117 consecutive DLBCL patients aged over 18 years old who received Pola-R-CHP as first-line therapy to investigate efficacy and safety from April 1, 2023, to October 31, 2024. Polatuzumab vedotin was administered 1.8 mg/KG, rituximab 375 mg/m

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsLymphoma, Large B-Cell, DiffuseAdolescentAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCyclophosphamideDoxorubicinEpirubicinFemaleHumansImmunoconjugatesMaleMiddle AgedPrednisoneAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedCyclophosphamideDoxorubicinEpirubicinImmunoconjugatespolatuzumab vedotinPrednisoneRituximabDiffuse large B-cell lymphomaFirst-lineLow riskPolatuzumab vedotinTrial-ineligible

Identifiers

PMID40728626
PMCPMC12432059

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.